Hengrui Medicine gains approval for HRS-8829 clinical trials

Jiangsu Hengrui Medicine [SSE:600276] announced that its subsidiary, Beijing Shengdi Pharmaceutical, has received a "Drug Clinical Trial Approval Notice" from the National Medical Products Administration of China for HRS-8829 injection. The drug, a small molecule intended for the treatment of acute ischemic stroke, will now proceed to clinical trials. Preclinical studies have suggested HRS-8829 can significantly reduce neurological deficits, reduce cerebral infarction and edema, inhibit inflammatory factor expression, improve the reduction of cerebral neurons, and inhibit neuronal apoptosis. As of now, the cumulative research and development investment in HRS-8829 injection totals CNY 9.74 million. The company cautioned that the drug's development is subject to uncertainties and that it will continue to fulfill its information disclosure obligations regarding the project's progress.